300030.SZ
Improve Medical Instruments Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 5.95
−2.62%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 466.0M | 486.3M | 581.3M | 644.6M | 710.8M |
| Cost of Revenue | 255.1M | 277.1M | 340.7M | 387.9M | 446.3M |
| Gross Profit | 210.9M | 209.1M | 240.6M | 256.7M | 264.4M |
| Operating Expenses | |||||
| R&D Expense | 22.0M | 23.7M | 31.9M | 37.5M | 43.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 69.5M | 74.2M | 86.9M | 106.7M | 113.4M |
| Selling & Marketing Expense | 64.7M | 66.1M | 93.9M | 118.4M | 126.0M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 164.0M | 175.5M | 229.9M | 287.6M | 306.4M |
| Cost and Expenses | 419.1M | 452.6M | 570.6M | 675.5M | 752.8M |
| Operating Income (EBIT) | 39.1M | 20.9M | (116.9M) | (40.8M) | (212.8M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 40.8M | 22.7M | (120.3M) | (43.1M) | (214.3M) |
| Income Tax Expense | 11.4M | 7.5M | (447.1K) | 17.2M | (21.0M) |
| Bottom Line | |||||
| Net Income | 28.4M | 14.5M | (117.9M) | (63.2M) | (198.3M) |
| Earnings from Cont. Ops | 29.3M | 15.2M | (119.9M) | (60.2M) | (193.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 28.4M | 14.5M | (117.9M) | (63.2M) | (198.3M) |
| Per Share | |||||
| Basic EPS | CN¥0.09 | CN¥0.05 | (CN¥0.38) | (CN¥0.20) | (CN¥0.64) |
| Diluted EPS | CN¥0.09 | CN¥0.05 | (CN¥0.38) | (CN¥0.20) | (CN¥0.64) |
| Revenue Per Share | CN¥1.50 | CN¥1.67 | CN¥1.87 | CN¥2.04 | CN¥2.29 |
| Shares | |||||
| Basic Shares Outstanding | 309.7M | 290.6M | 310.3M | 316.0M | 309.8M |
| Diluted Shares Outstanding | 309.7M | 290.6M | 310.3M | 316.0M | 309.8M |
| Profitability Metrics | |||||
| EBITDA | — | 53.7M | (80.0M) | (1.8M) | (170.9M) |
| D&A | — | 32.9M | 36.9M | 39.0M | 41.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026